Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/01/2005WO2005113494A2 Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
12/01/2005WO2005113490A1 Sulfone-containing prodrugs
12/01/2005WO2005113486A1 Carboxamido opioid compounds
12/01/2005WO2005113484A1 Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
12/01/2005WO2005113483A2 Levalbuterol hydrochloride polymorph a
12/01/2005WO2005113482A1 Levalbuterol hydrochloride polymorph b
12/01/2005WO2005113481A1 Preparation of levalbuterol hydrochloride
12/01/2005WO2005113069A2 Use of circumin and analogues as inhibitors of acc2
12/01/2005WO2005113023A1 Use of arginine and like substances and methylglyoxal and like substances in dialysis machines
12/01/2005WO2005113018A2 Cancer treatment using viruses and camptothecins
12/01/2005WO2005113014A1 siRNA TO VP-1 OF JC VIRUS AND MEDICINAL COMPOSITION CONTAINING THE SAME
12/01/2005WO2005113012A2 Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
12/01/2005WO2005113009A1 Solid pharmaceutical formulation
12/01/2005WO2005113007A2 Powders containing novel oligosaccharide mixtures and methods for producing the same
12/01/2005WO2005113006A2 Use of dipyridamole for treatment of resistance to platelet inhibitors
12/01/2005WO2005113004A2 Small molecule inhibitors for mrp1 and other multidrug transporters
12/01/2005WO2005113003A2 Method for augmenting b cell depletion
12/01/2005WO2005113002A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
12/01/2005WO2005112992A1 P. gingivalis vaccine
12/01/2005WO2005112990A2 Treatment of diseases associated with the use of antibiotics
12/01/2005WO2005112974A2 Peptide-modified polyurethane compositions and associated methods
12/01/2005WO2005112965A2 Botanical anti-inflammatory compositions and methods
12/01/2005WO2005112964A1 Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
12/01/2005WO2005112963A2 Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals
12/01/2005WO2005112960A1 Treatment for asthma and arthritis and othe inflammatory diseases
12/01/2005WO2005112957A1 Treatment of lung diseases and pre-lung disease conditions
12/01/2005WO2005112955A1 A composition for prevention and treatment of colon adenomas
12/01/2005WO2005112954A1 Nitric oxide releasing compositions and associated methods
12/01/2005WO2005112953A2 Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors
12/01/2005WO2005112952A2 Geldanamycin compounds and method of use
12/01/2005WO2005112951A1 Antitumor agent, method of producing antitumor agent, medicinal composition containing antitumor agent and microorganism producing antitumor agent
12/01/2005WO2005112950A1 Spinosyns for wound healing
12/01/2005WO2005112949A1 Use of drug combinations for treating insulin resistance
12/01/2005WO2005112948A1 Drug for remedy or treatment of wound
12/01/2005WO2005112947A2 Use of atp for the manufacture of a medicament for the prevention and treatment of oxidative stress and related conditions
12/01/2005WO2005112946A1 Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
12/01/2005WO2005112945A2 Synthesis of tetracyclines and analogues thereof
12/01/2005WO2005112944A1 Drug for prevention or treatment of diabetes
12/01/2005WO2005112943A1 Topical cromolyn formulations
12/01/2005WO2005112942A1 Methods and related compositions for reduction of fat
12/01/2005WO2005112941A2 Substituted cyclic urea derivatives
12/01/2005WO2005112940A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors
12/01/2005WO2005112939A1 Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction
12/01/2005WO2005112938A2 Disalt inhibitors of il-12 production
12/01/2005WO2005112937A1 Acyclovir formulations
12/01/2005WO2005112936A1 Compositions and methods relating to protein kinase inhibitors
12/01/2005WO2005112935A1 Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
12/01/2005WO2005112934A1 Pharmaceutical compositions comprising zd6474
12/01/2005WO2005112933A2 Substituted organosulfur compounds and methods of using thereof
12/01/2005WO2005112932A2 Raf modulators and methods of use
12/01/2005WO2005112931A2 Methods related to the treatment of neurodegenerative and inflammatory conditions
12/01/2005WO2005112930A1 Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
12/01/2005WO2005112929A2 Anti-hiv-1 activity of betulinol derivatives
12/01/2005WO2005112928A1 Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
12/01/2005WO2005112927A1 Selective serotonin receptor inverse agonists as therapeutics for disease
12/01/2005WO2005112926A1 Compositions and methods for treating or preventing pain
12/01/2005WO2005112925A1 Aryl sulfonamides
12/01/2005WO2005112924A2 Methods of treating cancer by inhibiting histone gene expression
12/01/2005WO2005112923A2 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
12/01/2005WO2005112922A2 Benzamide compounds
12/01/2005WO2005112921A2 Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
12/01/2005WO2005112920A1 Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
12/01/2005WO2005112918A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
12/01/2005WO2005112917A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
12/01/2005WO2005112916A2 Bis-aryl sulfonamides
12/01/2005WO2005112915A2 Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
12/01/2005WO2005112914A2 Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
12/01/2005WO2005112913A1 Transthyretin stabilization
12/01/2005WO2005112912A1 Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
12/01/2005WO2005112911A2 Compositions and methods for treating myelin deficiency disorders
12/01/2005WO2005112910A1 Combinations of hyaluronic acid and polyunsaturated fatty acids
12/01/2005WO2005112909A1 Anti-inflammatory analgesic external aqueous liquid preparation
12/01/2005WO2005112908A1 Method for improving cognitive function
12/01/2005WO2005112907A2 Nontoxic killer of e. coli and other problem microorganisms
12/01/2005WO2005112906A2 Method for augmenting the effects of serotonin reuptake inhibitors
12/01/2005WO2005112905A1 Method of treating dry eye disorders and uveitis
12/01/2005WO2005112904A1 Peroxisome proliferator-activated receptor (ppar) activator and drugs, supplements, functional foods and food additives using the same
12/01/2005WO2005112903A2 Use of ghrelin antagonists for improving cognition and memory
12/01/2005WO2005112902A2 Medicinal aerosol formulation products with improved chemical stability
12/01/2005WO2005112889A2 Transmucosal delivery formulations
12/01/2005WO2005112884A1 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer
12/01/2005WO2005112883A1 Preserved pharmaceutical compositions comprising cyclodextrins
12/01/2005WO2005112872A1 Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
12/01/2005WO2005112740A2 Noninvasive glucose sensor
12/01/2005WO2005112648A1 Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake
12/01/2005WO2005112646A2 Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
12/01/2005WO2005112637A1 Formulations for non-parenteral use including hydrophobic cyclodextrins
12/01/2005WO2005112635A2 Uridine effects on dopamine release
12/01/2005WO2005112633A2 Compounds and compositions for delivering active agents
12/01/2005WO2005112538A2 Use of adrenergic n-phenylpiperazine antagonists, pharmaceutical compositions containing them, and methods of preparing them.
12/01/2005WO2005099776A9 Steroid sparing agents and methods of using same
12/01/2005WO2005099680A3 Use of treprostinil to treat neuropathic diabetic foot ulcers
12/01/2005WO2005095403A3 Macrocyclic compounds as inhibitors of viral replication
12/01/2005WO2005095345A3 Heteroaryl guanidines as inhibitors of viral replication
12/01/2005WO2005094803A3 N3-pyridyl-thiamine and its use in cancer treatments
12/01/2005WO2005094797A3 Use of ampa-receptor antagonists for treating dementia
12/01/2005WO2005092310A3 Chemically stable compositions of 4-hydroxy tamoxifen
12/01/2005WO2005092308A3 Neural tourniquet
12/01/2005WO2005090383A3 Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
12/01/2005WO2005090301B1 Crystalline form of atorvastatin hemi calcium
1 ... 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 ... 7860